IBRX News and Press, ImmunityBio Inc. From 02/23/26

2026-02-23 18:33:18 ET Denver, Colorado - Midday trading is being shaped by a powerful mix of biotech momentum, breakthrough materials science, and strategic buyouts, as investors rotate toward companies delivering tangible catalysts. Spider Silk Headlines Power Materials Story ...

Biopharma & Cigalah are two of the largest pharmaceutical commercial distributors in the Middle East and North Africa (MENA) ImmunityBio established a wholly owned subsidiary in the Kingdom of Saudi Arabia to support physicians and healthcare systems throughout the MENA region The Reg...

2026-02-19 09:32:36 ET More on ImmunityBio ImmunityBio: The Story Surrounding Anktiva So Far ImmunityBio: Making Strides, But Beware The Hype (Rating Downgrade) ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Immu...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 3.4% to $1.71 on volume of 583,873,529 shares Rackspace Technology Inc. (RXT) rose 227.0% to $1.37 on volume of 542,491,528 shares RenX Enterprises Corp. (RENX) rose 44.9% to $0.19...

ImmunityBio partner Accord Healthcare to deploy an 85-person sales force to drive ANKTIVA commercialization across 30 countries Dublin-based subsidiary to support ImmunityBio’s distribution and commercialization strategy in Europe Distribution partnership supports ImmunityBioȁ...

2026-02-18 17:37:57 ET ImmunityBio (NASDAQ:IBRX) , which develops immunotherapies and vaccines for cancers and infectious diseases, closed Wednesday at $8.54, up 41.86%. The stock jumped after the European Commission granted conditional marketing authorization for Anktiva to treat b...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 0.8% to $1.755 on volume of 511,769,332 shares Rackspace Technology Inc. (RXT) rose 216.2% to $1.325 on volume of 500,182,029 shares RenX Enterprises Corp. (RENX) rose 41.5% to $0....

2026-02-18 14:10:58 ET Wednesday's trading session is proving to be a thrilling one for ImmunityBio (NASDAQ: IBRX) shareholders. As of 1:50 p.m. ET today the biopharma stock is up an incredible 33.1%. The reason? Unsurprisingly, an approval of its breadwinning drug in another hu...

2026-02-18 10:06:01 ET More on ImmunityBio ImmunityBio: The Story Surrounding Anktiva So Far ImmunityBio: Making Strides, But Beware The Hype (Rating Downgrade) ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Immu...

ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors, where no treatment was previously authorized for BCG-unrespon...